Researchers from Auburn University, partnering with the University of Basel in Switzerland, have discovered a new way to make ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...
CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ...
With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. The transaction is part ...
BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...
November 07, 2024--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that in a recent meeting the U.S ...
The PERLA trial showed consistent OS benefits across various PD-L1 tumor proportion scores, favoring Jemperli over Keytruda.
With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. The transaction is part ...
Key data: These results compare favourably to the 22.0-month median OS, 9.0-month median PFS, and 24-month OS rate of 45.5% from a registrational trial of anti-PD-1 and doublet chemotherapy in ...
Scientists at Auburn University have made an important discovery that could improve cancer treatments. Just like a coach ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback